Showing results (681-690 of 1,647) with videos related to
Sort By:
Pageof 165
Therapeutic Innovation & Regulatory Science|October 5, 2019
In Vitro Skin Permeation Methodology for Over-The-Counter Topical Dermatologic ProductsLuke Oh, Sojeong Yi, Da Zhang, et al.Therapeutic Innovation & Regulatory Science|March 3, 2021
Predictability of Severe Adverse Events in Phase 3 Trials from Safety Information on Phase 1 Trials in Oncology Drug DevelopmentTakashi Sawada, Masayuki Kaneko, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|March 23, 2021
Aggregate Safety Assessment Planning for the Drug Development Life-CycleBarbara A Hendrickson, William Wang, Greg Ball, et al.Therapeutic Innovation & Regulatory Science|November 8, 2021
Real World Evidence in Medical Cannabis ResearchRishi Banerjee, Simon Erridge, Oliver Salazar, et al.Therapeutic Innovation & Regulatory Science|February 6, 2022
Estimation of the Under-Reporting of Suspected Serious Adverse Drug Reactions in Japan Using An Interrupted Time Series AnalysisSatoru Ito, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|February 7, 2022
Status of Planned and Ongoing Paediatric Trials Investigating COVID-19 Vaccines: A Cross-Sectional Study of Paediatric Clinical Trials Planned in Agreed PIPs and/or Registered in Clinical Trial DatabasesHelle Christiansen, Steffen Thirstrup, Christine Erikstrup HallgreenTherapeutic Innovation & Regulatory Science|February 9, 2022
Integrative Analysis of Randomized Clinical Trial and Observational Study Data to Inform Post-marketing Safety Decision-MakingLi-An Lin, Yafei Zhang, Walter Straus, et al.Therapeutic Innovation & Regulatory Science|July 30, 2022
Over-Prescription of the Imidazoline Receptor Agonists: Evidence for Restriction of the Therapeutic IndicationRimas Jankūnas, Diana Rinkūnienė, Donatas StakišaitisTherapeutic Innovation & Regulatory Science|May 16, 2018
Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master ProtocolsTahira Khan, Mark Stewart, Samuel Blackman, et al.Therapeutic Innovation & Regulatory Science|May 18, 2018
Risk-Based Monitoring (RBM) Implementation: Challenges and Potential SolutionsNimita Limaye, Veena JagustePageof 165